Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 16:6:23281.
doi: 10.1038/srep23281.

Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains

Fuyuki Kametani  1 , Tomokazu Obi  2 , Takeo Shishido  2 , Hiroyasu Akatsu  3 , Shigeo Murayama  4 , Yuko Saito  5 , Mari Yoshida  6 , Masato Hasegawa  1
Affiliations

Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains

Fuyuki Kametani et al. Sci Rep. .

Abstract

TDP-43 is the major disease-associated protein involved in the pathogenesis and progression of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions linked to TDP-43 pathology (FTLD-TDP). Abnormal phosphorylation, truncation and cytoplasmic mis-localization are known to be the characteristics for the aggregated forms of TDP-43, and gain of toxic abnormal TDP-43 or loss of function of physiological TDP-43 have been suggested as the cause of neurodegeneration. However, most of the post-translational modifications or truncation sites in the abnormal TDP-43 in brains of patients remain to be identified by protein chemical analysis. In this study, we carried out a highly sensitive liquid chromatography-mass spectrometry analysis of Sarkosyl-insoluble pathological TDP-43 from brains of ALS patients and identified several novel phosphorylation sites, deamidation sites, and cleavage sites. Almost all modifications were localized in the Gly-rich C-terminal half. Most of the cleavage sites identified in this study are novel and are located in N-terminal half, suggesting that these sites may be more accessible to proteolytic enzymes. The data obtained in this study provide a foundation for the molecular mechanisms of TDP-43 aggregation and ALS pathogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1. SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotting of Sarkosyl-insoluble fraction from ALS case 1 brain and ALS case 2 brain.
(A) A phosphorylation-independent anti-TDP-43 detected normal TDP-43 of 43 kD in the fractions of both ALS and control brains, but also detected abnormal TDP-43 bands, including full-length phosphorylated TDP-43 of 45 kD, ~25 kD fragments and smears in ALS brains. (B) TDP-43-positive bands were excised as indicated.
Figure 2
Figure 2. MS/MS identification of phosphorylated peptides and cleavage site peptides.
Representative peptides were shown. (A) Chymotriptic peptide, 398-NGGFGSSM-405 in case 1. The 6th Ser residue was phosphorylated. (B)Triptic peptide, 56-LVEGILHAPDAGWGNLVYVVNYPK-79 in case 1. (C) Tryptic peptide, 215- GDVMDVFIPKPFR-227 in case 1. Trypsin can not cleave N-terminal Tyr214-Gly215 site. Therefore this site is intrinsically cleaved site. (D) Chymotryptic peptide, 56-LVEGILHAPDAGW-68 in case 2. Chymotrypsin can not cleave N-terminal Arg55-Leu56 site. Therefore this site is intrinsically cleaved site.
Figure 3
Figure 3
Identification of modification sites in TDP-43 from ALS case 1 (A) and case 2 (B) by LC-MS/MS analysis. Identified peptides from trypsin digestion (light green) and from chymotrypsin digestion (dark green) are shown. p indicates phosphorylation site. o indicates oxidation site. * indicates deamidation site. Blue and pink arrows indicate N-terminal and C-terminal cleavage sites, respectively.
Figure 4
Figure 4. Schematic representation of N-terminal and C-terminal cleavage sites on TDP-43.
Cleavage sites (amino acid numbering of TDP-43) in gel fractions and antibodies recognition sites were shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Buratti E. et al. TDP-43 Binds Heterogeneous Nuclear Ribonucleoprotein A/B through Its C-terminal Tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulatior exon 9 splicing. J. Biol. Chem. 280, 37572–37584, 10.1074/jbc.M505557200 (2005). - DOI - PubMed
    1. Baralle M., Buratti E. & Baralle F. E. The role of TDP-43 in the pathogenesis of ALS and FTLD. Biochem Soc Trans 41, 1536–1540, 10.1042/bst20130186 (2013). - DOI - PubMed
    1. Ayala Y. M., Misteli T. & Baralle F. E. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci USA 105, 3785–3789, 10.1073/pnas.0800546105 (2008). - DOI - PMC - PubMed
    1. Ayala Y. M., Pagani F. & Baralle F. E. TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett 580, 1339–1344, 10.1016/j.febslet.2006.01.052 (2006). - DOI - PubMed
    1. Corrado L. et al. High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Human Mutation 30, 688–694 (2009). - PubMed

Publication types